Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Synuclein Therapeutic Acceleration Program, 2013
    Pre-clinical Development of a Vaccine Against Alpha-synuclein Based on Virus-like Particles

    Objective/Rationale:             
    Overexpression of the protein alpha-synuclein has been identified as a major cause for the development of Parkinson’s disease (PD) in humans. Lewy bodies, which...

  • Synuclein Therapeutic Acceleration Program, 2013
    Development of the Alpha-Synuclein Stabilizer NPT200-11 for the Treatment of Parkinson’s Disease

    Objective/Rationale: 
    A role for the synaptic protein alpha-synuclein in Parkinson’s disease is suggested by human genetic studies, the histopathology in patients with Parkinson’s disease and studies...

  • Rapid Response Innovation Awards, 2013
    Alpha-Synuclein Effects on Fusion Pore Expansion and Protein Secretion

    Objective/Rationale:
    Alpha-synuclein, implicated in Parkinson’s disease, is normally expressed in nerve terminals, from which neurotransmitters are released by fusion of their granule membrane with the...

  • Therapeutic Pipeline Program, 2013
    Synthetic Nurr1 Ligands as Novel Neuroprotective Therapeutics to Treat Parkinson’s Disease

    Objective/Rationale:             
    The orphan nuclear receptor Nurr1 plays a critical role in the development and maintenance of midbrain dopamine neurons. Recent research also shows that it protects...

  • Therapeutic Pipeline Program, 2013
    Novel, Small Molecule Transforming Growth Factor Beta Agonist

    Objective/Rationale:             
    This project aims to develop a small molecule-based therapeutic targeting transforming growth factor beta (TGFB) signaling for the treatment of Parkinson’s disease (PD...

  • LRRK2 Pharmacodynamic Assays, 2013
    Measuring LRRK2 Cellular Function in Parkinson’s iPSC-Derived Dopaminergic Neurons

    Objective/Rationale:             
    We aim to develop a time-lapse, imaging, pharmacodynamic assay for measuring LRRK2 cellular function in dopaminergic (DA) neurons derived from human induced...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.